Sara Claire Horton | University of Iowa Clinical Research and Trials

Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

Studies

NMTRC014: Beat Childhood Cancer

Cancer Pediatrics Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects Female Subjects Male Subjects

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

BCC015 : Beat Childhood Cancer

Cancer Pediatrics Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects Female Subjects Male Subjects

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.